First Trust Advisors LP Acquires 105,245 Shares of Krystal Biotech, Inc. $KRYS

First Trust Advisors LP raised its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 42.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 350,521 shares of the company’s stock after acquiring an additional 105,245 shares during the quarter. First Trust Advisors LP’s holdings in Krystal Biotech were worth $90,547,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in KRYS. Soleus Capital Management L.P. boosted its holdings in shares of Krystal Biotech by 108.9% in the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares during the period. Norges Bank purchased a new stake in Krystal Biotech in the 4th quarter worth $70,159,000. William Blair Investment Management LLC raised its position in shares of Krystal Biotech by 152.1% in the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after buying an additional 227,038 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Krystal Biotech by 2,078.9% in the fourth quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock valued at $54,147,000 after purchasing an additional 209,369 shares during the period. Finally, UBS Group AG lifted its position in Krystal Biotech by 970.8% in the fourth quarter. UBS Group AG now owns 159,595 shares of the company’s stock valued at $39,347,000 after buying an additional 177,922 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

KRYS has been the topic of a number of recent research reports. Jefferies Financial Group reiterated a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a research note on Monday, July 13th. HC Wainwright upped their target price on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research note on Tuesday, June 16th. Wall Street Zen cut shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings downgraded shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, July 1st. Finally, Bank of America increased their price objective on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $360.67.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $335.19 on Friday. Krystal Biotech, Inc. has a 1-year low of $130.50 and a 1-year high of $382.54. The company has a market cap of $9.88 billion, a PE ratio of 44.81 and a beta of 0.50. The stock has a fifty day moving average price of $333.77 and a 200 day moving average price of $292.52.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.38. The company had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. Analysts anticipate that Krystal Biotech, Inc. will post 7.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 26,642 shares of company stock valued at $8,243,923. 13.10% of the stock is owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.